Royal Bank of Canada’s NeuroSense Therapeutics NRSN Stock Holding History

Royal Bank of Canada’s Portfolio NRSN Stock Details NRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-125	Closed	–	–	7596
2022 Q1	$0	Buy	+125	New	+$297	﹤0.01%	7925

Other funds holding NRSN

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

VPIM

Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return

Royal Bank of Canada's NRSN Position: Q2 2022 in Review

Royal Bank of Canada sold out of NeuroSense Therapeutics (NRSN) in Q2 2022, closing a stake of 125 shares.

Royal Bank of Canada first reported a position in NRSN in Q1 2022 and held it in 1 quarter. The position peaked at $0 in Q1 2022. 7 funds tracked by Wall St. Rank hold NRSN as of Q2 2022.

Royal Bank of Canada reported no remaining NeuroSense Therapeutics position as of Q2 2022 after selling out during the quarter.
Royal Bank of Canada sold 125 NeuroSense Therapeutics shares in Q2 2022.
Royal Bank of Canada first reported a position in NeuroSense Therapeutics in Q1 2022 and held it in 1 quarter.
Royal Bank of Canada's NeuroSense Therapeutics position peaked at $0 in Q1 2022.
7 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q2 2022.

Based on Royal Bank of Canada's 13F filing for Q2 2022, filed 15 Aug 2022.